Anzeige
Mehr »
Login
Montag, 27.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
US-Präsident setzt auf die Solana Blockchain! Diese Krypto-Perle profitiert enorm!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
700 Leser
Artikel bewerten:
(2)

Viatris: Building Pandemic Preparedness

Finanznachrichten News

NORTHAMPTON, MA / ACCESSWIRE / September 18, 2023 / Viatris

Viatris at UNGA

All countries face risks and potential health threats from an increasing range of factors including infectious diseases, food contamination and threats associated with climate change, extreme weather events and deforestation. Strengthening prevention and preparedness activities can pre-emptively avoid outbreaks, or contain them early on, reduce the possibility of conflicts becoming complex humanitarian health crises, and mitigate the impact of natural disasters.

The United Nations General Assembly (UNGA) 2023 High-level Meeting (HLM) on pandemic prevention, preparedness and response is a unique opportunity for global leaders to place health high on the political agenda and commit to bolstering resilient health systems for pandemic preparedness.

At Viatris, we are working with stakeholders across the globe to prepare for future pandemics. The work includes understanding how healthcare providers and systems can better help patients and respond to the needs of communities.

Building resilient health systems that can meet patient needs on an ongoing basis and respond rapidly and equitably to surges of infectious disease is critical. Our diverse efforts to advance this preparation include the following:

  • Viatris represents the private sector on the Board of the Global Fund to fight AIDS, TB and Malaria, a unique public-private partnership and one of the largest international financing mechanisms for healthcare delivery. The Global Fund comprises 30% of the international financing for HIV programs, 75% for TB programs and 60% for malaria programs.1 In response to COVID-19, the Global Fund also became a primary funder of programs for COVID-19 and pandemic preparedness in low-income countries. The unique partnership model of the Global Fund brings together the public and private sectors with impacted communities to develop people-centered access solutions.
  • Viatris has worked to understand not only the physical health effects of the pandemic, but also the mental effects. For example, in Brazil we sponsored a study of more than 2,000 workers of the impact of COVID-19 on mental health and wellbeing. The research was conducted by the Getúlio Vargas Foundation and the University of São Paulo. The findings are being used to help shape mental health and oncology policies as well as raise awareness of the important role of patient involvement.
  • Building on our work born from the pandemic that identified gaps and potential solutions for integrating care of HIV and NCDs, we leveraged our partnership with the NCD Alliance in 2022 to advocate and raise awareness of the issues at events including the UN Global Assembly (UNGA) 2022 and the International AIDS Society annual conference. We helped develop an advocacy toolkit targeted at national and regional NCD alliances to unlock local funding for NCDs and its comorbidities.
  • We collaborated in Japan with Minacare and a specialist in health, health policy and internal medicine on the first study investigating the changes in physician visits and medication prescriptions for NCDs before and during the COVID-19 pandemic. The findings will inform decision makers about the management of NCDs in future pandemics.

For more information, see our 2022 Sustainability Report.



View additional multimedia and more ESG storytelling from Viatris on 3blmedia.com.

Contact Info:
Spokesperson: Viatris
Website: https://www.3blmedia.com/profiles/viatris
Email: info@3blmedia.com

SOURCE: Viatris

View source version on accesswire.com:
https://www.accesswire.com/785093/building-pandemic-preparedness

© 2023 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.